Remove Antibody Remove Genetic Engineering Remove In-Vitro Remove Trials
article thumbnail

Brain Awareness Week 2024: A Spotlight on Brain Health and New Treatments for Neurological Diseases

XTalks

This includes discussions on cutting-edge technologies and methodologies in brain research, such as neuroimaging, genetic engineering and artificial intelligence. This relates to neurological conditions like dementia and Alzheimer’s disease, which account for up to 70 percent of dementia cases.

article thumbnail

Using bispecific antibodies to advance cancer immunotherapy

pharmaphorum

Dr Laura Moriarty, senior marketing manager at Bio-Rad, looks at the impressive immuno-therapeutic potential of bispecific antibodies (bsAbs). In 2019, there were 57 bsAb candidates in clinical trials, against both haematological and solid tumours.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How mice with humanised immune systems are advancing cell-based immunotherapy

Drug Discovery World

For example, in randomised clinical trials of patients with non-small cell lung cancer (NSCLC), pembrolizumab has been shown to be effective in slowing down disease progression and improving survival rates 1. However, adverse effects such as cytokine release syndrome (CRS) and neurotoxicity still occur. Jespersen et al.

In-Vivo 52
article thumbnail

The evolution of assays for immuno-oncology research

Drug Discovery World

Genetically modified T cells stimulated with IL2 are now administered as cell therapy for multiple cancer cell types with beneficial results 3,4. Over 250 clinical trials are currently in progress, and novel immuno-oncological treatments are already proving to be successful. This continues to be the standard of care.